$AKTS News

HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35

Aktis Oncology's AKY-2519 Shows Robust Tumor Uptake And Favorable Dosimetry Across Solid Tumors In First-In-Human B7-H3 Radiopharmaceutical Data Presented At ASCO 2026

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate

Aktis Oncology to Present at the BofA Securities Health Care Conference

Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Aktis Oncology Starts Phase 1b Clinical Study Of AKY-25191 In Participants With Metastatic Castration-resistant Prostate Cancer

William Blair Initiates Coverage On Aktis Oncology with Outperform Rating

Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

TAktis Oncology To Present First Clinical Imaging And Dosimetry Data For AKY-2519 At the 2026 American Society of Clinical Oncology Annual Meeting

Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know

Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33

Aktis Oncology shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $30 to $33.

HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $33

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

FDA Clears IND Application For Aktis Oncology To Proceed To Phase 1b Clinical Trial With AKY-2519